{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0042993_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"179-420-121-532-584"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8892,"type":"PATENT","title":"University of Wisconsin Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15082,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8214,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners = \"Wisconsin University\" , \"University of Wisconsin\", \"Wisconsin Univ\", \" Univ Wisconsin\" , \"Wisco* Alum* Res* Found*\".
Select more for logical variants
Add to collection
Search Applicants and Owners = \"Wisconsin University\" , \"University of Wisconsin\", \"Wisconsin Univ\", \" Univ Wisconsin\" , \"Wisco* Alum* Res* Found*\".
Select more for logical variants
Add to collection
a) reacting a protein, an ER-derived vesicle, and an acetyl-CoA; and\n
b) measuring the amount of post-translationally modified protein,\n
wherein the post-translational modification comprises acetylation of the protein in the ER-derived vesicle."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the protein is aspartic peptidase."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the aspartic peptidase is BACE1."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the ER-derived vesicle comprises an acetyl-CoA transporter."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein the acetyl-CoA transporter is AT-1."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein providing a protein further comprises providing purified, isolated, or recombinant protein."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the acetylation comprises acetylation of one or more lysine residues of the protein."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 further comprising reacting the protein, the ER-derived vesicle, and the acetyl-CoA with a Golgi vesicle, wherein the post-translational modification comprises acetylation of the protein in the ER-derived vesicle, and deacetylation of the protein in the Golgi vesicle."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which is conducted in an animal model or clinical trials."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which is conducted in a cell culture."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating Alzheimer's disease, comprising reducing the acetyl-CoA transport activity of AT-1 in the endoplasmic reticulum of a subject with Alzheimer's disease."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, comprising administering a therapeutically effective amount of an inhibitor of AT-1 activity to the subject, wherein the inhibitor of AT-1 activity reduces or eliminates the acetyl-CoA transport activity of AT-1 in the endoplasmic reticulum."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating Alzheimer's disease, comprising reducing the translocation of an aspartic peptidase from the ER into the Golgi of a subject with Alzheimer's disease."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the aspartic peptidase is BACE1."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, which is conducted in an animal model or clinical trials."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["An in vitro method for identification of a candidate compound as a compound that may be useful for the treatment of Alzheimer's disease, the method comprising the steps of:\n
a) providing a cell expressing an enzyme that acetylates an aspartic peptidase in the ER, wherein the acetylation is required for translocation of the aspartic peptidase from the ER into the Golgi;\n
b) contacting the cell with the candidate compound; and\n
c) measuring the amount of aspartic peptidase translocated from the ER into the Golgi,\n
wherein a decrease in amount of the aspartic peptidase, relative to the amount of aspartic peptidase translocated from the ER into the Golgi by a cell expressing the enzyme but not contacted with the candidate compound, identifies the candidate compound as a compound that may be useful for the treatment of Alzheimer's disease."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein the aspartic peptidase is BACE1."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein the enzyme is AT-1."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["An in vitro method for identification of a candidate compound as a compound that may be useful for the treatment of Alzheimer's disease, the method comprising the steps of:\n
a) providing a cell expressing an enzyme that acetylates BACE1 in the ER;\n
b) contacting the cell with the candidate compound; and\n
c) measuring translocation of the BACE1 from the ER into the Golgi,\n
wherein a decrease in the translocation, relative to the translocation by a cell expressing the enzyme but not contacted with the candidate compound, identifies the candidate compound as a compound that may be useful for the treatment of Alzheimer's disease."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the enzyme is AT-1."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the cell expresses a second enzyme that deacetylates BACE1 in the Golgi."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A screening method for testing a compound for its ability to inhibit acetylation of a protein in the ER, comprising:\n
a) reacting a protein that is acetylated in the ER, AT-1, and acetyl-CoA; and\n
b) measuring the amount of protein acetylated in the ER,\n
wherein a decrease in the amount of acetylated protein, relative to the amount of acetylated protein in the absence of the candidate compound, identifies the candidate compound as a compound that may be useful for the inhibition of protein acetylation in the ER."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the protein is BACE1."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, which is conducted in an animal model or clinical trials."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, which is conducted in a cell culture."],"number":25,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}